Blog

Tom Powles: Unsung Prostate Cancer Hero – David Olmos

Tom Powles and David Olmos

Jun 4, 2025, 04:07

Tom Powles: Unsung Prostate Cancer Hero – David Olmos

Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared a post on X:

“Uromigos unsung prostate cancer hero ASC025 – David Olmos – 50% 8 year OS for M1 1st line disease – but subgroups (PSMA+ve and BRCA) still have less good outcomes.

Opportunities for further therapy here with PARPi and LuPSMA (+ve PSMA addition and amplitude studies).”

Tom Powles shared findings from ASC025, citing a 50% 8-year overall survival in first-line metastatic prostate cancer. He noted poorer outcomes in PSMA-positive and BRCA subgroups, pointing to PARP inhibitors and LuPSMA as avenues for further therapeutic development.

More posts featuring Tom Powles.

ASC025 Barts Cancer Centre BRCA cancer David Olmos fight against cancer Global fight against cancer LuPSMA OncoDaily Oncology PARPi prostate cancer PSMA+ve Tom Powles University of London Uromigos

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment